GSK (FKA Glaxosmithkline INC.)
Based in DC
AI Overview
With $39.9M in lobbying spend across 35 quarterly filings, GSK (FKA Glaxosmithkline INC.) is one of the biggest lobbying spenders in Washington. They deploy 16 individual lobbyists Their lobbying covers 5 issue areas. Active from 2018 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $4.6M |
| 2019 | $4.4M |
| 2020 | $3.8M |
| 2021 | $6.3M |
| 2022 | $5.3M |
| 2023 | $5.1M |
| 2024 | $4.8M |
| 2025 | $5.6M |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that GSK (FKA Glaxosmithkline INC.) disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Trade, Copyright/Patent, Medicare/Medicaid, Budget/Appropriations
H.R. 449: Synthetic Drug Awareness Act: Provisions related to synthetic drug report
H.R. 749: Lower Drug Costs through Competition Act - Provisions related to generic drug approvals
H.R. 878: Right to
Trade Agreements and related policy issues
Biopharmaceutical innovation policy issues
International intellectual property and market access policy issues
Pricing and reimbursement policy issues
Canada
H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent Settlements
H.R. 5340: The Support Technology & Research for Our Nati
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.